Clinical trials: Women Diagnosed With Cancer
Breast Neoplasms, Breast Cancer Detection
Diagnostic Accuracy of Carebot AI MMG in Mammography Screening: Multicenter MRMC Study
This study evaluates the diagnostic performance of Carebot AI MMG, an artificial intelligence (AI)-enabled medical device for evaluating mammograms.
- Conditions
- Breast Neoplasms, Breast Cancer Detection, Breast Cancer - Female, Breast Cancer Screening
- Trial name
- CARE-MMG-MRMC (NCT07298252)
- Testing
- Carebot AI MMG software analysis
- Where
- 4 sites in Czechia, Slovakia
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Carebot s.r.o.
Cytoreductive Surgery, Grade 3 Endometrial Endometrioid Adenocarcinoma
PET/MRI in Endometrial Cancer
This study is investigating if positron emission tomography (PET)/Magnetic resonance imaging (MRI) is more effective than the currently used imaging modalities (computed tomography [CT], or PET/CT) for high-risk endometrial…
- Conditions
- Cytoreductive Surgery, Grade 3 Endometrial Endometrioid Adenocarcinoma, High Grade Serous Carcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT05390021
- Testing
- PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00959244
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Nebraska
Ovarian Carcinoma, Ovarian Cancer
Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses
This study is performed to compare the diagnostic performance and cost-effectiveness of different diagnostic methods for differentiating benign from malignant adnexal (ovary or Fallopian tube) masses: the Risk of Malignancy Index…
- Conditions
- Ovarian Carcinoma, Ovarian Cancer, Ovarian Mass, Ovarian Cyst
- Trial name
- SUBSONiC (NCT02218502)
- Testing
- Ultrasound by general gynaecologist, Ultrasound by an expert ultrasonographist, DW-MRI
- Where
- 5 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- Maastricht University Medical Center
Fallopian Tube Cancer, Ovarian Cancer
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed; giving…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00075712
- Testing
- carboplatin, paclitaxel, adjuvant therapy
- Where
- 70 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Royal College of Obstetricians and Gynecologists
Cervical Intraepithelial Neoplasia 3
Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation
This study is to follow up on the change of immune response by measuring HPV type 16/18 E6 and E7 specific T cell response and lesion condition in subjects who have administered in DNA-based therapeutic vaccine.
- Trial name
- GX-188E (NCT02411019)
- Testing
- GX-188E
- Where
- South Korea
- Volunteers
- 67 people
- Sponsor
- Genexine, Inc.
Solid Tumors, Carcinoma
Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors
This study aims to evaluate the performance of a novel SPECT imaging agent, 111In-TJD-31, which targets placental alkaline phosphatase (ALPP).
- Conditions
- Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant
- Trial name
- NCT07815951
- Testing
- 111In-TJD-31 Injection
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Yong He
Prostate Cancer, Benign Prostatic Hypertrophy
Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
This is a double-blind, study to evaluate the performance of NV-VPAC1 PCa Urine Diagnostic Test in three distinct populations being treated at the Intermountain Urology Clinic.
- Conditions
- Prostate Cancer, Benign Prostatic Hypertrophy, Bladder Stones, Kidney Stones
- Trial name
- VPAC (NCT03630926)
- Testing
- NV-VPAC1 PCa Urine Diagnostic Test
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Intermountain Health Care, Inc.
Carcinoma, Renal Cell, Clear Cell Renal Cell Carcinoma
Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC
89Zr-TLX250 is a carbonic anydrase IX (CAIX)-targeted imaging agent that is under clinical development as a non-invasive diagnostic imaging agent for teh detection of clear cell renal cell carcinoma (ccRCC).
- Trial name
- ZIRDAC-JP (NCT04496089)
- Testing
- 89Zr-girentuximab
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Upper Tract Urothelial Carcinoma
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
This study is evaluating whether a medication called 5-aminolevulinic acid (5-ALA), approved by the FDA for use in brain surgery, can help improve the visibility of upper tract urothelial tumors during surgery.
- Trial name
- NCT06948552
- Testing
- 5-Aminolevulinic acid Hydrochloride (Gliolan®)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Henry Ford Health System
Breast Cancer, Contralateral Breast Cancer
Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) may improve the ability to detect cancer in the unaffected breast of women recently diagnosed with unilateral breast cancer.
- Trial name
- ACRIN-6667 (NCT00058058)
- Testing
- MRI
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 1,007 people
- Sponsor
- American College of Radiology Imaging Network
Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement
Introduction Cervical intraepithelial neoplasia CIN1 (low grade), CIN2 (moderate grade), CIN3 (severe grade) defines cervical precancer lesions derived from the squamous epithelial cell line.
- Trial name
- NCT05049252
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
Colorectal Cancer, Gastric Cancers
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal…
- Conditions
- Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07219238
- Testing
- GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
- Where
- 2 sites in United States, Sweden
- Volunteers
- 175 people
- Sponsor
- GE Healthcare
Neoplasms, Lung Neoplasms
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to…
- Conditions
- Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms
- Trial name
- N1 (NCT02900248)
- Testing
- Provider determined
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- CureOne
Multiple Myeloma, Renal Failure
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed…
- Trial name
- NCT06142396
- Testing
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Augusta University
Hematuria, Bladder Cancer
Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With Hematuria
Our goal is to develop a noninvasive, fast and simple assay to detect BCa on the GeneXpert system and metablomic genes.
- Trial name
- NCT04317261
- Testing
- Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)
- Where
- Egypt
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Ovarian Cancer
Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.
The study is observational, not interventional. The study will include patients with advanced ovarian cancer who have been treated in Poland based on a previous early access program, and who are currently being treated under the…
- Trial name
- NIRAPARIB (NCT06614790)
- Testing
- Niraparib 200/300 MG
- Where
- 12 sites in Poland
- Volunteers
- 300 people
- Sponsor
- Pomeranian Medical University Szczecin
Breast Cancer
Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery
RATIONALE: Comparing results of diagnostic procedures performed before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment.
- Trial name
- NCT00033397
- Testing
- biopsy, magnetic resonance imaging, radiomammography
- Where
- 5 sites in United States
- Volunteers
- 360 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Ovarian Cancer
Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)
Objectives: To evaluate the attitudes and opinions of women undergoing genetic counseling for hereditary breast and ovarian cancer syndrome, both before and after testing, in regards to pregnancy and fertility Hypothesis…
- Trial name
- NCT00829959
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center